Compare AbbVie Inc (ABBV) vs Nvidia Corp (NVDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Nvidia Corp — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Nvidia Corp trades at $202.74 (market cap $4.77T). The key difference: Nvidia Corp is far larger — about 10.6× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NVDA | |
|---|---|---|
Market Cap | $449.91B | $4.77T |
Sector | Health | Technology |
52-Week High | $261.07 | $235.75 |
52-Week Low | $184.85 | $160.00 |
Enterprise Value | $513.38B | $4.70T |
Dividend Yield | 2.72% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
NVDA trades at $204.08, up 4.36% today, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 EPS of $1.87, beating expectations, and maintains exceptional profitability with a 62.97% net income margin. Revenue growth accelerated to $130.5B in 2025, though technical indicators show resistance near $207 and support at $185.
Outlook remains positive with a consensus price target of $324.95, implying 59% upside, supported by AI chip dominance. Risks include peak AI spending concerns and increased competition. Wall Street sentiment is bullish with 75% buy ratings, but near-term technical weakness suggests potential consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
